Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
Author:
Funder
Compagnia di San Paolo
Associazione Italiana per la Ricerca sul Cancro
Publisher
Elsevier BV
Subject
Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine
Reference242 articles.
1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N. Engl. J. Med.,2012
2. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012
3. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N. Engl. J. Med.,2013
4. CTLA-4 and PD-1 pathway blockade: combinations in the clinic;Callahan;Front. Oncol.,2015
5. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Maintaining the Balance: Regulation of NK Cell Activity;Cells;2024-08-31
2. Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells;Frontiers in Immunology;2024-07-15
3. Region‐Specific CD16+ Neutrophils Promote Colorectal Cancer Progression by Inhibiting Natural Killer Cells;Advanced Science;2024-05-24
4. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors;Journal for ImmunoTherapy of Cancer;2024-02
5. Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors;Cancer Pathogenesis and Therapy;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3